As 2017 comes to a close, we leave behind an exciting and fulfilling year at The Oral Cancer Foundation. After nearly 17 years of helping to better the lives of those affected by this deadly disease, the year reflects another where our engagement has increased. The areas in which we interact with patients, treatment professionals, researchers, policy professionals at the NIH and its subordinate organizations, and the dental community who are part of the early discovery paradigm, continues to increase as well. 2017 has seen OCF develop countless new relationships that have helped us further our missions. For this, we are immensely grateful. With a total of 30 walks/run fundraising events this year, we have been fortunate to have patients, survivors, dental professionals, volunteers, and donors support us along the way. The community that has continued to grow around us has made OCF a relevant force in this battle. With your generosity and hard work, we have been able to build the structure of a bigger picture we hope to fulfill- a society with the understanding and scientific technology to not only treat oral cancer more effectively, but to be educated enough to be engaged in self-discovery of signs and symptoms that will catch it at the earliest stages. Every contribution- be it big or small, is funding that enhanced future for those affected by oral cancer, while enabling others to avoid risk factors that bring them to it, or teach individuals to find it early should it enter their lives. The Oral Cancer Foundation is dedicated to expanding research to better understand and fight this disease. That is why each year OCF funds a variety of scientific researchers working in the field of oral cancer. This year and continuing into 2018, we are once again proudly working with Maura Gillison, MD, head and neck medical oncologist and molecular epidemiologist at MD Anderson Cancer Center. Your donations have been partially applied to her latest research in immunotherapy including modifying and targeting more precisely through gene editing Car-T Cells which have been effective in other cancers for use in head and neck malignancies. Our commitment to her in this work is a multi-year grant and continues for 2 more years. Gillison’s pioneering research in another immunotherapy contributed to the development of the breakthrough immune checkpoint inhibitor drugs that are now FDA approved for patients in the head and neck community. We also supported Dr’s Fakhry and D’Souza at Johns Hopkins Cancer Center who help us understand at a population level, the impact of having an oral HPV16 infection, and what does that infection mean in actual numbers of individuals that will ultimately cascade into a cancer. Now, with important new ideas ready to enter clinical trials, more than ever we need the support of those who fight alongside us as donors to this work. As the giving season approaches, we hope you will again choose to support OCF so we may continue our funding of the sciences, and the patient centric support, and community outreach in prevention that we engage in. From all of us at The Oral Cancer Foundation, we are proud to have so many inspiring and committed allies. May the New Year bring good fortune and health to you all.